Literature DB >> 33250338

Slowed Processing Speed Disrupts Patient Expectancy in Late Life Depression.

Bret R Rutherford1, C Jean Choi2, Jongwoo Choi2, Ben Mass3, Xiaofu He2, Kaleigh O'Boyle2, Joel Sneed4, Patrick J Brown3, Adam Brickman3, Melanie M Wall3, Steven P Roose3.   

Abstract

OBJECTIVE: Slowed processing speed and executive dysfunction are associated with poor outcomes in Late Life Depression (LLD), though it is unclear why. We investigated whether these variables interfere with the development of positive treatment expectancies in an antidepressant trial.
METHODS: Depressed older subjects were randomized to Open (intended to increase patient expectancy) or Placebo-controlled (termed 'Hidden,' intended to decrease expectancy) administration of antidepressant medication for 8 weeks. Analysis of covariance analyzed the between-group difference on expectancy (Credibility and Expectancy Scale [CES]) and depression (Hamilton Rating Scale for Depression [HRSD], Clinical Global Impressions [CGI] Severity). Moderator analyses examined whether these Open versus Hidden differences varied based on higher versus lower processing speed and executive function.
RESULTS: Among the 108 participants, a significant between-group difference was observed on expectancy (effect size [ES, Cohen's d] = 0.51 on CES Item 2; ES = 0.64 on Item 4), indicating the manipulation was effective. Processing speed as measured by the Stroop Color-Word Test (number color-words named in congruent condition) was a significant moderator of the Open versus Hidden effect on expectancy. Depressive symptom improvement was greater on average for Open versus Hidden participants who received active drug (CGI-severity ES = 1.25, HRSD ES = 0.41), but no neurocognitive moderators of the between-group difference reached statistical significance.
CONCLUSIONS: Slowed processing speed impairs the development of expectancies in antidepressant trials for LLD, which may help explain lower antidepressant response among older adults. Future studies may address whether interventions to optimize treatment expectancies are capable of improving treatment outcomes.
Copyright © 2020 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Late life depression; antidepressants; executive dysfunction; expectancy; processing speed

Mesh:

Substances:

Year:  2020        PMID: 33250338      PMCID: PMC8099936          DOI: 10.1016/j.jagp.2020.11.001

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   7.996


  36 in total

1.  Psychometric properties of the credibility/expectancy questionnaire.

Authors:  G J Devilly; T D Borkovec
Journal:  J Behav Ther Exp Psychiatry       Date:  2000-06

2.  Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression.

Authors:  Marta Peciña; Amy S B Bohnert; Magdalena Sikora; Erich T Avery; Scott A Langenecker; Brian J Mickey; Jon-Kar Zubieta
Journal:  JAMA Psychiatry       Date:  2015-11       Impact factor: 21.596

Review 3.  A Meta-Analysis of Executive Dysfunction and Antidepressant Treatment Response in Late-Life Depression.

Authors:  Monique A Pimontel; David Rindskopf; Bret R Rutherford; Patrick J Brown; Steven P Roose; Joel R Sneed
Journal:  Am J Geriatr Psychiatry       Date:  2015-05-21       Impact factor: 4.105

Review 4.  Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression.

Authors:  Joel R Sneed; Bret R Rutherford; David Rindskopf; David T Lane; Harold A Sackeim; Steven P Roose
Journal:  Am J Geriatr Psychiatry       Date:  2007-11-12       Impact factor: 4.105

5.  Clinical and neuroradiologic features associated with chronicity in late-life depression.

Authors:  H Lavretsky; I M Lesser; M Wohl; B L Miller; C M Mehringer
Journal:  Am J Geriatr Psychiatry       Date:  1999       Impact factor: 4.105

Review 6.  Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

Authors:  George I Papakostas; Maurizio Fava
Journal:  Eur Neuropsychopharmacol       Date:  2008-09-26       Impact factor: 4.600

Review 7.  A model of placebo response in antidepressant clinical trials.

Authors:  Bret R Rutherford; Steven P Roose
Journal:  Am J Psychiatry       Date:  2013-07       Impact factor: 18.112

8.  Patient Expectancy as a Mediator of Placebo Effects in Antidepressant Clinical Trials.

Authors:  Bret R Rutherford; Melanie M Wall; Patrick J Brown; Tse-Hwei Choo; Tor D Wager; Bradley S Peterson; Sarah Chung; Irving Kirsch; Steven P Roose
Journal:  Am J Psychiatry       Date:  2016-09-09       Impact factor: 18.112

9.  The nature and determinants of neuropsychological functioning in late-life depression.

Authors:  Meryl A Butters; Ellen M Whyte; Robert D Nebes; Amy E Begley; Mary Amanda Dew; Benoit H Mulsant; Michelle D Zmuda; Rishi Bhalla; Carolyn Cidis Meltzer; Bruce G Pollock; Charles F Reynolds; James T Becker
Journal:  Arch Gen Psychiatry       Date:  2004-06

10.  Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor.

Authors:  C Anacker; P A Zunszain; A Cattaneo; L A Carvalho; M J Garabedian; S Thuret; J Price; C M Pariante
Journal:  Mol Psychiatry       Date:  2011-04-12       Impact factor: 15.992

View more
  2 in total

1.  Association of White Matter Integrity With Executive Function and Antidepressant Treatment Outcome in Patients With Late-Life Depression.

Authors:  Xiaofu He; Elena Pueraro; Yoojean Kim; Carolina Montes Garcia; Ben Maas; Jongwoo Choi; Dakota A Egglefield; Sophie Schiff; Joel R Sneed; Patrick J Brown; Adam M Brickman; Steven P Roose; Bret R Rutherford
Journal:  Am J Geriatr Psychiatry       Date:  2021-01-23       Impact factor: 4.105

2.  Who benefits most from expectancy effects? A combined neuroimaging and antidepressant trial in depressed older adults.

Authors:  Sigal Zilcha-Mano; Meredith L Wallace; Patrick J Brown; Joel Sneed; Steven P Roose; Bret R Rutherford
Journal:  Transl Psychiatry       Date:  2021-09-15       Impact factor: 7.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.